Arrive AIARAI
Recorded

Arrive AI 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration43 minParticipants8

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good morning, everyone, and thank you for joining us today. On the call are Dan O'Toole, Arrive AI's Chairman, CEO, and Founder; Piyush Phadke, Chief Financial Officer; Bill Karwoski, Chief Revenue Officer; John Ritchison, Chief Legal Officer; and Neerav Shah, Chief Strategy Officer. Other members of the leadership team are also here to answer questions during the Q&A portion of the call. The press release issued this morning is available in the investor relations section of the company's website at investors.arriveai.com. Before we begin, please note that today's remarks may include forward-looking statements about future financial results, operations, and performance. These statements are not guaranteed and are subject to risk and uncertainties that could cause actual results to differ materially. We encourage investors to review the risk factors in Arrive AI's SEC filings, which are available on the company's website. I will now turn the call over to Dan O'Toole.

Dan O'TooleChairman, CEO, and Founder

Thanks, Shannon. Good morning, everyone. This is Dan O'Toole here. We'll keep our prepared comments short so that we can spend most of the time on answering questions. One development I'm particularly pleased with is our growing relationship with our great partners at Hancock Health. Hancock expanded its use of Arrive Points during the third quarter and added the connectivity of a second building, which drove our third-quarter revenue. That expansion shows how we plan to grow, demonstrate the value of our technology, and then build on that success across our customers' facilities. It also gives us a reference customer as we pursue other hospitals and healthcare systems. They have been great partners in opening up their facility to showcase what we have going at their facility, and we're really proud of that. Revenue remains modest but expanding as we would expect.

Dan O'TooleChairman, CEO, and Founder

Relationships with existing customers is an important part of building a recurring revenue base. With that said, I will also be covering broader progress with customers and partners. Piyush, our CFO, will then cover our financial results, liquidity, and the steps we have taken to address our Nasdaq listing requirements. Neerav will then provide an update on the defense division that we just recently formed. Bill Karwoski, our recently appointed Chief Revenue Officer, is here and will introduce himself as well. The first part of our prepared remarks from Piyush and me will be delivered using the AI-assisted voice as always. Neerav and Bill will then speak live, and we will tell you when we switch back to live.

Dan O'TooleChairman, CEO, and Founder

Now, let me add some more detail on the expansion at Hancock. We added a new Arrive Point at their Parkway Building to work with the hospital's existing delivery robot, supporting four to five scheduled specimen pickups a day for delivery to the laboratory with on-demand service for urgent specimens. This puts our technology to work in another part of the hospital's daily operations, and for the first time, it connects a separate building. Building on that work, we are expanding our partnership with Ottonomy, the autonomous delivery robot company supporting deliveries at Hancock. As part of our recently announced strategic investment in Ottonomy, we received three autonomous robots and entered into a supply agreement that contemplates bringing up to 50 ground robots to our partner locations. The partnership gives us a way to bring these technologies together at additional locations, extending the approach already in use at Hancock.

Dan O'TooleChairman, CEO, and Founder

Outside of healthcare, on October 29th, we announced the installation of two Arrive Point AP3+ units in Central Indiana, marking our first installation in a commercial office setting. This will help us understand how people use a secure delivery point in their daily routines and refine our approach as we pursue opportunities in the commercial office market. Since July, we have also announced several initiatives that expand the potential applications of Arrive Point technology. In specialty pharmacy, we signed a non-binding letter of intent with LifeSpan Pharmacy to explore a drone pharmacy delivery program. In manufacturing, we announced a partnership with DXC Technology to bring Arrive Points into large manufacturing campuses. These give us opportunities in two distinct markets. We are also working with Modovolo on automated drone delivery. In parallel, we are in early discussions with Purdue University about testing Arrive Point technology with robot platforms on campus.

Dan O'TooleChairman, CEO, and Founder

These initiatives with LifeSpan, DXC, Modovolo, and Purdue are at varying stages of development and do not currently include revenue commitments, but they broaden the potential applications of our technology and complement the revenue-generating work already underway at Hancock. We are also in active conversations with a number of organizations, including venues and local governments. We are not naming them today as we treat an agreement as firm only once it is signed, and we will announce each one when it is. Supporting these efforts is the continued development of our Arrive Point technology. The AP3+ became available for shipping on October 7th, adding edge computing and onboard vision. These capabilities allow the unit to detect packages and track them through the chain of custody, supporting the secure automated handoffs at the center of our delivery model. To date, we have 16 units in our fleet available for deployment.

Dan O'TooleChairman, CEO, and Founder

With that, I will hand it over to Piyush.

Piyush PhadkeCFO

Thanks, Dan, and good morning. I will start with the third-quarter results and liquidity, then cover our Nasdaq listing. Revenue for the third quarter was $39,700, made up of $25,000 in installation fees and $14,700 in monthly subscriptions, compared with $7,450 in the third quarter of last year. Net loss was $3.7 million, or $3.37 per share, compared with $4.4 million, or $6.39 per share in the third quarter of last year. Per-share amounts reflect the recently announced 1-for-48 reverse stock split. The smaller loss mainly reflects a lower non-cash loss on the conversion of convertible notes, partly offset by higher operating expenses. Cash and cash equivalents were $1.1 million, and investments at fair value were $1.0 million at September 30th, compared with cash and cash equivalents of $2.1 million and no investments at December 31st, 2025.

Piyush PhadkeCFO

Total operating expenses for the quarter were $3.3 million, compared with $1.7 million in the third quarter of last year. We are managing spending carefully and focusing our resources on our commercial delivery and product development. During the quarter, we streamlined our staffing and cost structure to better align with those priorities. Since quarter end, we completed a $250,000 private placement with an accredited investor and raised $1.3 million through our at-the-market program. Based on our current operating plan, we expect our available cash and investments to fund operations through the end of the year and into 2027. on October 27th, we completed our redomiciliation from Delaware to Nevada, which we reported on Form 8-K. Now, turning to our Nasdaq listing. On October 22nd, we announced Nasdaq's approval of our transfer to the Nasdaq Capital Market, effective October 23rd.

Piyush PhadkeCFO

The transfer resolved two listing deficiencies related to the market value of our listed securities and publicly held shares, leaving the Minimum Bid Price Requirement as the remaining deficiency. To address that requirement, we announced a 1-for-48 reverse stock split on November 10th. The split took effect at 12:01 A.M. on November 12th, and our shares began trading on a split-adjusted basis that morning under the same symbol, ARAI. This reduced our shares outstanding from approximately 68.8 million to approximately 1.4 million. The reverse split is intended to help us regain compliance with Nasdaq's Minimum Bid Price Requirement, which requires a closing bid price of at least $1 for a minimum of 10 consecutive business days. Throughout this process, our focus remains on building the business, managing costs, and growing revenue.

Operator

Neerav, over to you. I will now turn it back over to Arrive.

Neerav ShahChief Strategy Officer

Thanks, Dan, and thanks, Piyush. We're back to speaking with you live. On October 12th, we announced the formation of the Arrive AI Defense Division, which I lead, to explore applications of our technology in military defense and national security markets. The idea builds on what we already do, and Arrive Point provides a secure place where a drone or robot can be stored, charged, and deployed, and where goods can be exchanged without requiring two people to be present at the same time. We believe those same capabilities apply to defense applications, including the secure storage and launch of unmanned systems, including counter-UAS. Our core business remains focused on commercial delivery. The defense division gives us an opportunity to explore another market for the same underlying technology. Dan, back to you. Thanks, Neerav.

Dan O'TooleChairman, CEO, and Founder

I am happy to introduce today for the first time Bill Karwoski, our Chief Revenue Officer. This is the first time that we have had a CRO, Chief Revenue Officer, and I want to note that as a huge positive, because that shows our belief in the fact that we have revenue significant enough to support the formation of this role. I am counting on you, Bill, to bring it home and get us over to where we really want to be doing some big things here. So welcome to the team, and go take over here, man.

Bill KarwoskiChief Revenue Officer

Great, Dan. Thank you. Thank you so much. Hi, everyone. I am Bill Karwoski. I too am an investor in Arrive AI and recently came on board, as Dan mentioned, as Chief Revenue Officer. So I have got skin in the game, and I really want to see this work just as everyone in this room and everybody out there does as well. A little bit about me. I spent the last 40 years leading sales teams and working with Fortune 1000 companies in healthcare, pharma, manufacturing, and retail. The one thing that has kept me going all these years is delivering results you can actually measure, both for the clients and for the companies that I have worked for. That is why I am here. I am working with our team to target the right companies with the right solutions and drive revenue we can actually deliver on, and not just talk about.

Bill KarwoskiChief Revenue Officer

Right now, that means healthcare systems, pharma, and life sciences is primary. That is where we have got momentum, clients, and real opportunities in motions. We are pairing our secure Arrive Points with our robotics partners to solve everyday problems like lab movement, internal logistics, and keeping chain of custody tight on compliance-sensitive materials. Our job is to turn this into revenue now while we build our bigger pipeline in 2027 for all of us.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day